In a strategic move aimed at bolstering its biopharmaceutical endeavors, Pfizer, the renowned industry leader, is set to amplify its influence within Industrial Realty Group’s Hudson Valley iCampus located in Pearl River.
The augmentation entails Pfizer securing an expansive lease of 151,065 square feet across multiple buildings within the Hudson Valley iCampus locale. These facilities will serve as critical hubs for Pfizer’s scientific and biotechnological undertakings, as recently disclosed by Industrial Realty Group.
The allocated space will be a dedicated hub for Pfizer’s PGS division, a vital arm responsible for producing commercial antibody drug conjugates that contribute significantly to Pfizer’s oncology ventures.
Hudson Valley iCampus, a sprawling, multifunctional property sprawling across 2 million square feet, spanning 207 acres at 401 North Middletown Road in Pearl River, stands as the pivotal setting for this expansion. The site is currently home to a dynamic array of tenants including Pfizer, Sanofi US Services, Momentive Performance Materials, Auro Vaccines, and Strides Pharma.
In tandem with this expansion, Pfizer has unveiled ambitious plans to channel a substantial investment of $470 million. This funding will be directed toward the establishment of a state-of-the-art laboratory and office complex, specially dedicated to Pfizer’s vaccine research and development efforts. The chosen location for this innovative addition is a portion of Pfizer’s 23-acre parcel, situated adjacently to the Hudson Valley iCampus. The proposed facility will seamlessly extend Pfizer’s pre-existing laboratory, office, and meeting areas within the iCampus complex.
Representing the interests of ownership in Pfizer’s strategic advancement at the Hudson Valley iCampus is Jamie Schwartz, who holds the esteemed position of President at the campus. Pfizer’s side of the negotiation was artfully managed by Warren Braverman, a distinguished Senior Managing Director at Cushman & Wakefield (CWK).
As Pfizer consolidates its presence within the Hudson Valley iCampus in Pearl River, the global biopharmaceutical titan takes another resolute step forward in its mission to drive innovation, research, and development in the realm of life-changing medical solutions.